# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Roche's SKYSCRAPER-06 study of tiragolumab plus Tecentriq and chemotherapy did not meet primary endpoints for progression-f...
SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free s...
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that...
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractor...
The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism i...
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...
The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older w...
The solution, which includes the VENTANA DP 200 slide scanner, Roche's digital pathology workflow software and a display,...
– The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or r...